Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Interstitial lung disease
How do you approach the treatment of indeterminate UIP on HRCT with grossly positive MPO antibody and no other features consistent with AAV?
Related Questions
How would you approach medication de-escalation in a patient with a history of rapidly progressive CTD-ILD who responded to and is currently on mycophenolate 3 grams daily and IVIG 2mg/kg monthly infusions and has been stable for two years?
In a patient with antisynthetase syndrome (Jo-1+, ILD, and myositis) treated with IVIG, mycophenolate, and tacrolimus, would you stop the IVIG after lung transplant? Myositis has not been active. What is the risk of recurrence of ILD after lung transplant?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
Would nintedanib offer benefit to a patient with scleroderma (Anti-Th/To+/SSA+) who has CT chest with typical UIP pattern?
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
Are there patients with gout in whom you would choose febuxostat first line over allopurinol for urate lowering therapy?
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach treating patients with lupus profundus?
